Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up
Authors:
- D S OlssonDOD S Olsson
- M BuchfelderMBM Buchfelder
- K WiendieckKWK Wiendieck
- N KremenevskajaNKN Kremenevskaja
- B-Å BengtssonBBB-Å Bengtsson
- K-E JakobssonKJK-E Jakobsson
- M JarfeltMJM Jarfelt
- G JohannssonGJG Johannsson
- A G NilssonANA G Nilsson
- 1 June 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 166 (6) , 1061-1068
Abstract
Objective: Most patients who have been treated for craniopharyngioma (CP) are GH deficient (GHD). GH replacement therapy (GHRT) may stimulate tumour regrowth; and one of the concerns with long-term GHRT is the risk of tumour progression. Therefore, the objective was to study tumour progression in CP patients on long-term GHRT.Design: Case–control study.Patients and methods: The criteria for inclusion of cases were: i) GHD caused by CP; ii) GHRT >3 years; and iii) regular imaging. This resulted in 56 patients (mean age at diagnosis 25±16 years) with a mean duration of GHRT of 13.6±5.0 years. As controls, 70 CP patients who had not received GHRT were sampled with regard to follow-up, gender, age at diagnosis and initial radiation therapy (RT).Results: The 10-year tumour progression-free survival rate (PFSR) for the entire population was 72%. There was an association (hazard ratio, P value) between PFSR and initial RT (0.13, <0.001) and residual tumour (3.2, <0.001). The 10-year PFSR was 88% for the GHRT group and 57% for the control group. Substitution with GHRT resulted in the following associations to PFSR: GHRT (0.57, 0.17), initial RT (0.16, <0.001), residual tumour (2.6, <0.01) and gender (0.57, 0.10). Adjusted for these factors, the 10-year PFSR was 85% for the GHRT group and 65% for the control group.Conclusions: In patients with CP, the most important prognostic factors for the PFSR were initial RT and residual tumour after initial treatment. Long-term GHRT did not affect the PFSR in patients with CP.Keywords
This publication has 36 references indexed in Scilit:
- Analyses of Treatment Variables for Patients with Childhood Craniopharyngioma – Results of the Multicenter Prospective Trial KRANIOPHARYNGEOM 2000 after Three Years of Follow-UpHormone Research in Paediatrics, 2010
- Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapyEuropean Journal of Endocrinology, 2009
- Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniquesNeurosurgical Review, 2007
- GH replacement does not increase the risk of recurrence in patients with craniopharyngiomaClinical Endocrinology, 2006
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004
- Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adultsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- A Prospective Study of 5 Years of GH Replacement Therapy in GH-Deficient Adults: Sustained Effects on Body Composition, Bone Mass, and Metabolic IndicesThe Journal of Clinical Endocrinology & Metabolism, 2001
- Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adultsClinical Endocrinology, 1997
- Insulin‐like growth factor‐I in growth hormone‐deficient adults: relationship to population‐based normal values, body composition and insulin tolerance testClinical Endocrinology, 1997
- Reduced bone mineral density in patients with adult onset growth hormone deficiencyThe Journal of Clinical Endocrinology & Metabolism, 1994